Pediatrics, Neonatology, Center for Pediatric Clinical Effectiveness, Childrens Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Independent Statistician, Ottawa, Ontario, Canada.
Arch Dis Child Fetal Neonatal Ed. 2021 Nov;106(6):649-656. doi: 10.1136/archdischild-2020-320638. Epub 2021 May 6.
To determine the difference in rate of weight gain from birth to 5 years based on exposure to maternal group B streptococcal (GBS) intrapartum antibiotic prophylaxis (IAP).
Retrospective cohort study of 13 804 infants.
Two perinatal centres and a primary paediatric care network in Philadelphia.
Term infants born 2007-2012, followed longitudinally from birth to 5 years of age.
GBS IAP defined as penicillin, ampicillin, cefazolin, clindamycin or vancomycin administered ≥4 hours prior to delivery to the mother. Reference infants were defined as born to mothers without (vaginal delivery) or with other (caesarean delivery) intrapartum antibiotic exposure.
Difference in rate of weight change from birth to 5 years was assessed using longitudinal rate regression. Analysis was a priori stratified by delivery mode and adjusted for relevant covariates.
GBS IAP was administered to mothers of 2444/13 804 (17.7%) children. GBS IAP-exposed children had a significantly elevated rate of weight gain in the first 5 years among vaginally-born (adjusted rate difference 1.44% (95% CI 0.3% to 2.6%)) and caesarean-born (3.52% (95% CI 1.9% to 5.2%)) children. At 5 years, the rate differences equated to an additional 0.24 kg among vaginally-born children and 0.60 kg among caesarean-born children.
GBS-specific IAP was associated with a modest increase in rate of early childhood weight gain. GBS IAP is an effective intervention to prevent perinatal GBS disease-associated morbidity and mortality. However, these findings highlight the need to better understand effects of intrapartum antibiotic exposure on childhood growth and support efforts to develop alternate prevention strategies.
根据产妇接触 B 组链球菌(GBS)产时抗生素预防(IAP)的情况,确定从出生到 5 岁体重增加率的差异。
13804 例婴儿的回顾性队列研究。
费城的两个围产期中心和一个初级儿科保健网络。
2007-2012 年出生的足月婴儿,从出生到 5 岁进行纵向随访。
GBS IAP 定义为母亲在分娩前≥4 小时给予青霉素、氨苄西林、头孢唑林、克林霉素或万古霉素。参照婴儿定义为出生时母亲无(阴道分娩)或有其他(剖宫产)产时抗生素暴露的婴儿。
使用纵向速率回归评估从出生到 5 年体重变化率的差异。分析预先按分娩方式分层,并调整了相关协变量。
13804 例儿童中有 2444 例(17.7%)母亲接受了 GBS IAP。GBS IAP 暴露的儿童在阴道分娩(调整后的体重增加率差异为 1.44%(95%CI 0.3%至 2.6%))和剖宫产分娩(3.52%(95%CI 1.9%至 5.2%))的前 5 年体重增长速度明显加快。在 5 岁时,阴道分娩儿童的体重差异为 0.24 公斤,剖宫产分娩儿童的体重差异为 0.60 公斤。
GBS 特异性 IAP 与儿童早期体重增加率适度增加相关。GBS IAP 是预防围产期 GBS 疾病相关发病率和死亡率的有效干预措施。然而,这些发现强调了需要更好地了解产时抗生素暴露对儿童生长的影响,并支持努力开发替代预防策略。